Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its lead product is LIVMARLI (maralixibat), an orally administered ileal bile acid transporter (IBAT) inhibitor approved for cholestatic pruritus in Alagille syndrome patients in the United States and globally. The company also commercializes Cholbam (cholic acid) for bile acid synthesis disorders and peroxisomal disorders, and Chenodal for radiolucent gallstones and cerebrotendinous xanthomatosis. Additionally, Mirum is developing Volixibat (IBAT inhibitor) for cholestatic liver diseases, Brelovitug for chronic HDV infection, and MRM-3379 for fragile X syndrome.

Mirum Pharmaceuticals is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol MIRM. Its shares are traded in US dollars (USD), reflecting its primary listing in the United States. The company is headquartered in the United States and operates within the US region, with its stock available for trading on this major US exchange.

Mirum Pharmaceuticals operates in the Healthcare sector, specifically within the Biotechnology industry. As a biopharmaceutical company, it focuses on developing novel therapies for rare and orphan diseases, which are typically underserved by existing treatments. Its work involves research, clinical trials, and commercialization of drugs targeting conditions like Alagille syndrome, bile acid synthesis disorders, and cholestatic liver diseases.

Mirum Pharmaceuticals is headquartered in the United States and primarily serves the US market, though its products have global reach. For instance, LIVMARLI is approved for Alagille syndrome in the US and globally, and the company has collaboration agreements with international partners like Shire International GmbH. Its therapies target rare diseases worldwide, but the company's operations and stock listing are centered in the US.

Mirum Pharmaceuticals generates revenue by developing and commercializing therapies for rare and orphan diseases. Its approved products include LIVMARLI (for Alagille syndrome), Cholbam (for bile acid synthesis disorders), and Chenodal (for gallstones and cerebrotendinous xanthomatosis). The company also has a pipeline of candidates like Volixibat, Brelovitug, and MRM-3379, which may generate future revenue if approved. Additionally, Mirum has licensing agreements with Pfizer, Sanofi, and Novartis, which likely provide milestone payments or royalties.